

**Mountain-Pacific***Quality Health . . . The go-to resource for driving innovation in health care systems*

3404 Cooney Drive, Helena, MT 59602

Phone 406.443.6002 • Toll Free Phone 1.800.395.7961

Fax 406.513.1928 • Toll Free Fax 1.800.294.1350

Montana Medicaid Prior Authorization Request Form for Use of Sovaldi® (sofosbuvir)**Sovaldi® Initial Approval Form**

Patient's Name:	Patient's Medicaid ID#:
Patient's DOB:	Patient's Gender:
Provider's Name:	Provider's Specialty:
Provider's Phone #:	Provider's Fax #:
Today's Date:	Anticipated Sovaldi® Start Date:

I. Patient Readiness Evaluation:

Patient psychosocial readiness is a critical component for Hepatitis C treatment success. It is important that any potential impediments to the effectiveness of treatment have been identified and that a plan for dealing with these impediments has been developed. The patient must be educated that abuse of alcohol may cause further liver damage and that abuse of IV injectable drugs will increase the risk of re-infection of Hepatitis C if the virus is cleared. Given the high cost of Hepatitis C treatment, we want to ensure that both the provider and the patient feel that the patient is committed to effectively start and successfully adhere to treatment. We highly recommend that you use a patient readiness evaluation tool such as Prep-C, a free interactive online tool which can be found at the following website: <https://prepc.org/>. **Please discuss the following questions with your patient, document their responses below, and have patient sign page 2:**

1. **Does patient have a history of alcohol abuse?** Yes No
 - If yes, how long has it been since patient last used alcohol?
 - If yes, is patient attending a support group or receiving counseling? Yes No
2. **Does patient have a history of injectable drug abuse?** Yes No
 - If yes, how long has it been since patient last used an injectable drug?
 - If yes, is patient attending a support group or receiving counseling? Yes No
3. **Does patient have a history of any other controlled-substance abuse?** Yes No
 - If yes, how long has it been since patient last used this substance?
 - If yes, is patient attending a support group or receiving counseling? Yes No
4. **Does patient have difficulties with medication compliance and/or showing up for appointments?** Yes No
 - If yes, how will compliance/ involvement be improved?
5. **Does patient have mental health conditions that are not being adequately treated?** Yes No
 - If yes, please explain, and state the plan for treatment:
6. **Does patient have adequate social support?** Yes No
 - If not, please state a plan to improve support:

MT Medicaid Hepatitis C Patient Readiness Criteria:

1. Patient must not have a history of alcohol abuse, injectable drug abuse, and/or other controlled-substance abuse for at least 6 months prior to starting Hepatitis C treatment. Patient involvement in a support group or counseling is highly encouraged for successful abstinence.
2. Patient must be reasonably compliant with all current medications that are being prescribed for all disease states/conditions to be considered eligible for Hepatitis C treatment.
3. Patient must have a history of showing up for scheduled appointments/labs leading up to the prescribing of Hepatitis C treatment.
4. If patient has mental health conditions, patient must be compliant with mental health medications and/or psychotherapy. If patient has mental health conditions that are not currently being treated, then a mental health consult to assess for patient readiness will be required before Hepatitis C treatment can begin.

Patient signature: _____

Date: _____

II. MT Medicaid Sovaldi[®] Requirements:

A. Current quantitative HCV RNA results (attach results):

B. Documentation of extent of liver damage must be included [liver biopsy fibrosis stage (F0-F4), or any of the following non-invasive test results: APRI score, FibroSure score, or FibroScan results]

C. Please provide Child-Pugh Classification Score (by points)-score each of 5 measures in table below to calculate total points: _____

	Points Assigned		
PARAMETER	1	2	3
Ascites	Absent	Slight	Moderate
Bilirubin, total (mg/dL)	1.0-2.0	2.0-3.0	>3.0
Albumin (g/dL)	>3.5	2.8-3.5	<2.8
Prothrombin Time			
-Seconds prolonged	1.0-4.0	4.0-6.0	>6.0
-International normalized ratio (INR)	<1.7	1.7-2.3	>2.3
Encephalopathy*	None	Grade 1-2	Grade 3-4

*Encephalopathy is classified as Grade 0 to 4:

Grade

0-no abnormality detected

1-shortened attention span, impaired addition and subtraction skills, mild euphoria or anxiety

2-Lethargy, apathy, disoriented to time, personality change, inappropriate behavior

3-Somnolence, semi-stupor, responsive to stimuli, confused when awake, gross disorientation

4-Coma, little or no response to stimuli, mental state not testable

Child Pugh Grade	Description	Total Points
A	Mild; well-compensated disease	5-6
B	Moderate; significant functional compromise	7-9
C	Severe; decompensated disease	10-15

Adapted from: Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646-9. PMID:

D. List any previously tried Hepatitis C treatments, dates treated, and response:

E. Patient must meet ALL of the following criteria*: (Please check all that apply)

- ☐ All chart notes related to Hepatitis C evaluation/treatment must be included
- ☐ Patient Readiness Evaluation (page 1) must be completed and patient must meet all of the Patient Readiness Criteria listed on page 2
- ☐ Documentation of extent of liver damage must be included (see page 2)
 - ☐ Individual is considered at highest risk for Hepatitis-C related complications (must have liver fibrosis staging of F3 or F4, be a liver transplant recipient, or have severe extrahepatic manifestations)
- ☐ Patient must not have decompensated cirrhosis (based on Child-Pugh Score-see page 2)
- ☐ Diagnosis of chronic hepatitis C infection with HCV genotype 1, 2, 3, or 4
- ☐ Never had previous treatment with HCVNS3/4A protease inhibitors [ex: Incivek[®] (telaprevir), Victrelis[®] (boceprevir), or Olysio[®] (simeprevir)]
- ☐ Patient is 18 years of age or older
- ☐ Must be prescribed by (or had a documented consult with) a gastroenterologist, infectious disease specialist, or a practitioner specializing in the treatment of hepatitis. Notes of consultation with specialist must be attached.
- ☐ Female patient or male patient's female partner must not be pregnant or planning to become pregnant during treatment or within 6 months after stopping treatment (due to ribavirin).
- ☐ Sovaldi[®] must be taken along with required concomitant meds (ex: ribavirin or ribavirin + peginterferon alfa) depending on HCV genotype.
- ☐ Patient does not have severe renal impairment (CrCl <30ml/min) or end stage renal disease requiring dialysis.
- ☐ Patient must not have had treatment with any other Hepatitis C medications within the last 6 months.
- ☐ Patient must not be taking any of the following medications (please circle if patient is taking): carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifabutin, rifampin, rifapentine, St. John's wort, or tipranavir/ritonavir.

*Any requests not meeting criteria will require review by the MT Medicaid DUR Board

F. Patient must meet ONE of these criteria, as well as ALL criteria listed above:

(Check the one that applies)

- ☐ **HCV Genotype 1:** Sovaldi[®] will be used with peginterferon alfa and ribavirin for 12 weeks
- ☐ **HCV Genotype 1 (interferon ineligible):** Sovaldi[®] in combination with ribavirin (without peg interferon alfa) for 24 weeks may be considered for Genotype 1 patients who have an interferon contraindication. Please provide reason why interferon can't be used:

- ☐ **HCV Genotype 2:** Sovaldi[®] will be used with ribavirin for 12 weeks
- ☐ **HCV Genotype 3:** Sovaldi[®] will be used with ribavirin for 24 weeks
- ☐ **HCV Genotype 4:** Sovaldi[®] will be used with peginterferon alfa and ribavirin for 12 weeks
- ☐ **HCV Genotype 1,2, 3, or 4 with hepatocellular carcinoma meeting Milan criteria awaiting liver transplantation:** Sovaldi[®] will be used in combination with ribavirin for UP TO 48 weeks or until liver transplantation occurs, whichever occurs first, to prevent post-transplant HCV reinfection.

Limitations:

1. Quantity Limit of **28 tablets per 28 days** (one 400 mg tablet daily).
2. **Initial approval** will be granted for **8 weeks**.
3. Continuation of therapy beyond 8 weeks will require completion of **Sovaldi[®] Renewal Form** (page 4).

Provider's Signature: _____

Date: _____

**Please complete form, attach documentation, and fax to: Medicaid Drug Prior Authorization
Unit at 1-800-294-1350**

Page 3 of 3

Montana Medicaid Prior Authorization Request Form for Use of Sovaldi® (sofosbuvir)

Sovaldi® Renewal Form

Patient's Name:	Patient's Medicaid ID#:
Patient's DOB:	Patient's Gender:
Provider's Name:	Provider's Specialty:
Provider's Phone #:	Provider's Fax #:
Date:	

Date Sovaldi® was started: _____

HCV Genotype : (check one)

- ☐ HCV Genotype 1
- ☐ HCV Genotype 1 (interferon ineligible)
- ☐ HCV Genotype 2
- ☐ HCV Genotype 3
- ☐ HCV Genotype 4
- ☐ HCV Genotype 1,2,3, or 4 with hepatocellular carcinoma meeting Milan criteria awaiting liver transplantation

Renewal Requirements: All of the following requirements must be met: **(Please check all that apply)**

- ☐ Required concomitant medications (ribavirin or peginterferon alfa + ribavirin, depending on the HCV genotype) **must not have been discontinued.**
- ☐ Patient must have been **compliant** with Sovaldi® and required concomitant medications (ribavirin or peginterferon + ribavirin) as per protocol

Renewal Limitations:

1. Quantity Limit of **28 tablets per 28 days** (one 400 mg tablet daily).
2. If patient meets criteria, Sovaldi® will be approved as follows:
 - **HCV Genotype 1, 2, and 4:** Will be authorized for the remaining **4 weeks** of Sovaldi® (for a maximum total of 12 weeks)
 - **HCV Genotype 1 (interferon ineligible) and Genotype 3:** Will be authorized in **8 week increments** (for a maximum total of 24 weeks of Sovaldi®). Note: Sovaldi® Renewal Form will need to be submitted for each 8 week authorization.
 - **HCV Genotype 1,2,3, or 4 with hepatocellular carcinoma meeting Milan criteria awaiting liver transplantation:** Will be authorized in **8 week increments** (for a maximum total of 48 weeks or until liver transplantation occurs, whichever occurs first). Note: Sovaldi® Renewal Form will need to be submitted for each 8 week authorization.

Provider's Signature: _____

Date: _____